TY  - JOUR
AU  - Galldiks, Norbert
AU  - Abdulla, Diana SY
AU  - Scheffler, Matthias
AU  - Wolpert, Fabian
AU  - Werner, Jan-Michael
AU  - Huellner, Martin W
AU  - Stoffels, Gabriele
AU  - Schweinsberg, Viola
AU  - Schlaak, Max
AU  - Kreuzberg, Nicole
AU  - Landsberg, Jennifer
AU  - Lohmann, Philipp
AU  - Ceccon, Garry
AU  - Baues, Christian
AU  - Trommer, Maike
AU  - Celik, Eren
AU  - Ruge, Maximilian I
AU  - Kocher, Martin
AU  - Marnitz, Simone
AU  - Fink, Gereon R
AU  - Tonn, Joerg-Christian
AU  - Weller, Michael
AU  - Langen, Karl-Josef
AU  - Wolf, Jürgen
AU  - Mauch, Cornelia
TI  - Treatment Monitoring of Immunotherapy and Targeted Therapy using 18 F-FET PET in Patients with Melanoma and Lung Cancer Brain Metastases: Initial Experiences
JO  - Journal of nuclear medicine
VL  - 62
IS  - 4
SN  - 2159-662X
CY  - New York, NY
PB  - Soc.
M1  - FZJ-2021-00862
SP  - 464-470
PY  - 2021
AB  - We investigated the value of O-(2-18F-fluoroethyl)-l-tyrosine (18F-FET) PET for treatment monitoring of immune checkpoint inhibition (ICI) or targeted therapy (TT) alone or in combination with radiotherapy in patients with brain metastasis (BM) since contrast-enhanced MRI often remains inconclusive. Methods: We retrospectively identified 40 patients with 107 BMs secondary to melanoma (n = 29 with 75 BMs) or non–small cell lung cancer (n = 11 with 32 BMs) treated with ICI or TT who had 18F-FET PET (n = 60 scans) for treatment monitoring from 2015 to 2019. Most patients (n = 37; 92.5%) had radiotherapy during the course of the disease. In 27 patients, 18F-FET PET was used to differentiate treatment-related changes from BM relapse after ICI or TT. In 13 patients, 18F-FET PET was performed for response assessment to ICI or TT using baseline and follow-up scans (median time between scans, 4.2 mo). In all lesions, static and dynamic 18F-FET PET parameters were obtained (i.e., mean tumor-to-brain ratios [TBR], time-to-peak values). Diagnostic accuracies of PET parameters were evaluated by receiver-operating-characteristic analyses using the clinical follow-up or neuropathologic findings as a reference. Results: A TBR threshold of 1.95 differentiated BM relapse from treatment-related changes with an accuracy of 85% (P = 0.003). Metabolic responders to ICI or TT on 18F-FET PET had a significantly longer stable follow-up (threshold of TBR reduction relative to baseline, ≥10%; accuracy, 82%; P = 0.004). Furthermore, at follow-up, time to peak in metabolic responders increased significantly (P = 0.019). Conclusion: 18F-FET PET may add valuable information for treatment monitoring in BM patients treated with ICI or TT.
LB  - PUB:(DE-HGF)16
C6  - 32887757
UR  - <Go to ISI:>//WOS:000658416500008
DO  - DOI:10.2967/jnumed.120.248278
UR  - https://juser.fz-juelich.de/record/890281
ER  -